Affenadenovirus (gorilla) or adenoviral vectors and methods of use
The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexone protein, and/or fiber protein.
1. A method of delivering a non-native nucleic acid sequence to mammalian cells in vivo, wherein the method comprises in vivo administration of an adenovirus or adenoviral vector comprising a non-native nucleic acid sequence encoding an immunogenic protein and one or more of the nucleic acid sequences selected from the group consisting of:
(a) a nucleic acid sequence that is at least 98.5% identical to SEQ ID NO: 2,
(b) a nucleic acid sequence that is at least 80% identical to SEQ ID NO: 4, and
(c) a nucleic acid sequence that is at least 89% identical to SEQ ID NO: 5.
2. The method of claim 1 , wherein the adenovirus or adenoviral vector further comprises the nucleic acid sequence of SEQ ID NO: 1.
3. The method of claim 1 , wherein the adenovirus or adenoviral vector comprises a nucleic acid sequence that is at least 98.5% identical to SEQ ID NO: 2.
4. The method of claim 3 , wherein the adenovirus or adenoviral vector comprises the nucleic acid sequence of SEQ ID NO: 2.
5. The method of claim 1 , wherein the adenovirus or adenoviral vector further comprises a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 3.
6. The method of claim 5 , wherein the adenovirus or adenoviral vector comprises the nucleic acid sequence of SEQ ID NO: 3.
7. The method of claim 1 , wherein the adenovirus or adenoviral vector comprises a nucleic acid sequence that is at least 80% identical to SEQ ID NO: 4.
8. The method of claim 7 , wherein the adenovirus or adenoviral vector comprises the nucleic acid sequence of SEQ ID NO: 4.
9. The method of claim 1 , wherein the adenovirus or adenoviral vector comprises a nucleic acid sequence that is at least 89% identical to SEQ ID NO: 5.
10. The method of claim 9 , wherein the adenovirus or adenoviral vector comprises the nucleic acid sequence of SEQ ID NO: 5.
11. A method of delivering a non-native nucleic acid sequence to mammalian cells in vivo, wherein the method comprises in vivo administration of an adenovirus or adenoviral vector comprising a non-native nucleic acid sequence encoding an immunogenic protein and one or more of the amino acid sequences selected from the group consisting of:
(a) an amino acid sequence that is at least 80% identical to SEQ ID NO: 14, and
(b) an amino acid sequence that is at least 83% identical to SEQ ID NO: 15.
12. The method of claim 11 , wherein the adenovirus or adenoviral vector further comprises the amino acid sequence of SEQ ID NO: 11.
13. The method of claim 11 , wherein the adenovirus or adenoviral vector further comprises an amino acid sequence that is at least 82% identical to SEQ ID NO: 13.
14. The method of claim 13 , wherein the adenovirus or adenoviral vector comprises the amino acid sequence of SEQ ID NO: 13.
15. The method of claim 11 , wherein the adenovirus or adenoviral vector comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 14.
16. The method of claim 15 , wherein the adenovirus or adenoviral vector comprises the amino acid sequence of SEQ ID NO: 14.
17. The method of claim 11 , wherein the adenovirus or adenoviral vector comprises an amino acid sequence that is at least 83% identical to SEQ ID NO: 15.
18. The method of claim 17 , wherein the adenovirus or adenoviral vector comprises the amino acid sequence of SEQ ID NO: 15.
19. A method of delivering a non-native nucleic acid sequence to mammalian cells in vivo, wherein the method comprises in vivo administration of an adenovirus or adenoviral vector comprising a non-native nucleic acid sequence encoding an immunogenic protein and one or more of the nucleic acid sequences selected from the group consisting of:
(a) a nucleic acid sequence encoding an amino acid sequence that is at least 99.68% identical to SEQ ID NO: 12,
(b) a nucleic acid sequence encoding an amino acid sequence that is at least 80% identical to SEQ ID NO: 14, and
(c) a nucleic acid sequence encoding an amino acid sequence that is at least 83% identical to SEQ ID NO: 15.
20. The method of claim 19 , wherein the adenovirus or adenoviral vector further comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 11.
21. The method of claim 19 , wherein the adenovirus or adenoviral vector comprises a nucleic acid sequence encoding an amino acid sequence that is at least 99.68% identical to SEQ ID NO: 12.
22. The method of claim 21 , wherein the adenovirus or adenoviral vector comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 12.
23. The method of claim 19 , wherein the adenovirus or adenoviral vector further comprises a nucleic acid sequence encoding an amino acid sequence that is at least 82% identical to SEQ ID NO: 13.
24. The method of claim 23 , wherein the adenovirus or adenoviral vector comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 13.
25. The method of claim 19 , wherein the adenovirus or adenoviral vector comprises a nucleic acid sequence encoding an amino acid sequence that is at least 80% identical to SEQ ID NO: 14.
26. The method of claim 25 , wherein the adenovirus or adenoviral vector comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 14.
27. The method of claim 19 , wherein the adenovirus or adenoviral vector comprises a nucleic acid sequence encoding an amino acid sequence that is at least 83% identical to SEQ ID NO: 15.
28. The method of claim 27 , wherein the adenovirus or adenoviral vector comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 15.